Journal
CLINICAL IMMUNOLOGY
Volume 233, Issue -, Pages -Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2021.108887
Keywords
Idiopathic multicentric Castleman's disease; Tocilizumab; Sirolimus; mTOR; RNA-sequence
Categories
Ask authors/readers for more resources
mTOR signaling could potentially serve as a new therapeutic target for IL-6 inhibitor refractory iMCD-NOS.
mTOR signaling may be a new therapeutic target for IL-6 inhibitor refractory iMCD-NOS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
